Literature DB >> 9753473

Drug-resistant HIV-1 proteases identify enzyme residues important for substrate selection and catalytic rate.

T W Ridky1, A Kikonyogo, J Leis, S Gulnik, T Copeland, J Erickson, A Wlodawer, I Kurinov, R W Harrison, I T Weber.   

Abstract

A series of mutations, first identified in protease inhibitor-resistant HIV-1 viral isolates, were introduced into HIV-1 PR as individual substitutions. Mutants containing R8K, V32I, V82T, I84V, G48V/L90M, or V82T/I84V substitutions were analyzed for differences in substrate preference and catalytic efficiency using a set of single amino acid substituted HIV-1 CA-NCa cleavage site peptides. All mutants exhibited wild-type preference for large hydrophobic residues, especially Phe, in the P1' substrate position. Only the R8K and V32I mutants showed significant differences in subsite selection compared to wild-type enzyme. In a parallel study, the individual mutations R10K, L12V, I44V, A60M, I71V, and I108V were introduced into RSV PR. These amino acid positions are structurally equivalent to Arg8, Leu10, Val32, Met46, Ile54, and Ile84 in HIV-1 PR, respectively, which mutate in drug-resistance. The RSV R10K substitution significantly altered substrate specificity and catalytic rate, compared to wild-type, in a manner similar to that of the HIV-1 R8K mutant. Crystal structures of the RSV PR R10K, I44V, I71V, and Il08V mutant enzymes presented here indicate that each of these substitutions has little effect on the overall structure of the respective enzymes. Taken together, these data provide an explanation for the reported in vivo predilection for selection of large hydrophobic residues in the P1' substrate position of second locus mutations in the Gag polyprotein PR cleavage sites. The data also suggest that the selection of resistant enzymes is not simply limited to loss of binding to inhibitor but affects other steps in proteolysis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9753473     DOI: 10.1021/bi980612k

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  17 in total

1.  Altered substrate specificity of drug-resistant human immunodeficiency virus type 1 protease.

Authors:  Deborah S Dauber; Rainer Ziermann; Neil Parkin; Dustin J Maly; Sami Mahrus; Jennifer L Harris; Jon A Ellman; Christos Petropoulos; Charles S Craik
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

2.  Indinavir resistance evolution in one human immunodeficiency virus type 1 infected patient revealed by single-genome amplification.

Authors:  Qing-Mao Geng; Han-Ping Li; Zuo-Yi Bao; Yong-Jian Liu; Dao-Min Zhuang; Lin Li; Si-Yang Liu; Jing-Yun Li
Journal:  Virol Sin       Date:  2010-10-08       Impact factor: 4.327

3.  Identification of amino acids in HIV-1 and avian sarcoma virus integrase subsites required for specific recognition of the long terminal repeat Ends.

Authors:  Aiping Chen; Irene T Weber; Robert W Harrison; Jonathan Leis
Journal:  J Biol Chem       Date:  2005-11-18       Impact factor: 5.157

4.  Alteration of substrate and inhibitor specificity of feline immunodeficiency virus protease.

Authors:  Y C Lin; Z Beck; T Lee; V D Le; G M Morris; A J Olson; C H Wong; J H Elder
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

Review 5.  Positive and negative aspects of the human immunodeficiency virus protease: development of inhibitors versus its role in AIDS pathogenesis.

Authors:  K Ikuta; S Suzuki; H Horikoshi; T Mukai; R B Luftig
Journal:  Microbiol Mol Biol Rev       Date:  2000-12       Impact factor: 11.056

6.  Kinetic, stability, and structural changes in high-resolution crystal structures of HIV-1 protease with drug-resistant mutations L24I, I50V, and G73S.

Authors:  Fengling Liu; Peter I Boross; Yuan-Fang Wang; Jozsef Tozser; John M Louis; Robert W Harrison; Irene T Weber
Journal:  J Mol Biol       Date:  2005-10-21       Impact factor: 5.469

7.  HIV-1 Protease Uses Bi-Specific S2/S2' Subsites to Optimize Cleavage of Two Classes of Target Sites.

Authors:  Marc Potempa; Sook-Kyung Lee; Nese Kurt Yilmaz; Ellen A Nalivaika; Amy Rogers; Ean Spielvogel; Charles W Carter; Celia A Schiffer; Ronald Swanstrom
Journal:  J Mol Biol       Date:  2018-11-07       Impact factor: 5.469

8.  Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug.

Authors:  F Mammano; V Trouplin; V Zennou; F Clavel
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

9.  Replacement of the P1 amino acid of human immunodeficiency virus type 1 Gag processing sites can inhibit or enhance the rate of cleavage by the viral protease.

Authors:  Steve C Pettit; Gavin J Henderson; Celia A Schiffer; Ronald Swanstrom
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

10.  Drug resistance in HIV-1 protease: Flexibility-assisted mechanism of compensatory mutations.

Authors:  Stefano Piana; Paolo Carloni; Ursula Rothlisberger
Journal:  Protein Sci       Date:  2002-10       Impact factor: 6.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.